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Recently, Christoph Thiel and colleagues 
from Aachen University published an im-
proved physiologically based pharmacoki-
netik modeling (PBPK) technique for mouse 
to human extrapolation (Thiel et al., 2015). 
This publication will be awarded by the 
Ebert Prize 2016 of the American Pharmacist 
Association, which represents the oldest 
pharmacy award in the United States. 
The translation of preclinical knowledge 
often generated in mice to first-in-human 
studies represents a critical step (Thiel et al., 
2015). More than 30 % of developmental 
compounds fail due to interspecies differ-
ences. To improve the situation, the authors 
used PBPK modeling to predict human 
plasma concentration-time profiles based on 
mouse data. The study was based on 10 ex-
emplary drugs for which a comprehensive 
pharmacokinetic database is available. 
Mouse to human extrapolation was achieved 
by adjustment of four model parameter do-
mains (Thiel et al., 2015):  
(1) species-specific physiology, such as 
differences in organ size, perfusion, etc.  
(2) the species-specific non-protein 
bound fraction of the test compound,  
(3) kinetic parameters, such as Vmax and 
KM for the primary route of excretion, and 
(4) tissue-specific gene expression of the 
metabolizing key enzymes and transporters. 
The authors start with a naïve extrapola-
tion where humans are considered as ‘large 
mice’ where the same dose per body weight 
was administered (Thiel et al., 2015). This 
naïve extrapolation usually resulted in pre-
dictions that strongly deviate from the real 
human situation. Next the authors showed 
that knowledge-based adjustment of each of 
the four model domains leads to an im-
provement and allows predictions which 
closely resemble the measured situation in 
humans. A limitation of the current approach 
is that gene expression data were used to ad-
just for interspecies differences in metabo-
lism. In future, predictions may become even 
more accurate if RNA based data could be 
replaced by metabolic activities.  
Interspecies differences represent a major 
problem in toxicology (Dohnal et al., 2014; 
Bernauer et al., 2000; Brüning et al., 2014; 
Gerbracht and Spielmann, 1998; Unkila et 
al., 1995; Leist and Hartung, 2013). Rodent 
to human comparisons have often been per-
formed by comparing data in human and 
mouse or rat hepatocytes (Carmo et al., 
2004, 2005; Reder-Hilz et al., 2004; Hewitt 
et al., 2007; Gebhardt et al., 2003; Godoy et 
al., 2013; Hengstler et al., 1999). However, 
differences in metabolism represent only one 
of several aspects which can explain inter-
species differences.  
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PBPK modeling has been used since long 
to predict absorption, distribution, metabo-
lism and excretion (Sterner et al., 2013; Lee 
et al., 2007; Jonsson et al., 2001; El-Masri et 
al., 1996a, b). However, the approach pre-
sented by Thiel and colleagues (2015), in 
which all parameter domains relevant for 
interspecies differences can be stepwise ad-
justed, represents an important step to im-
prove extrapolations from rodent models to 
predict the human situation. 
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